Litigation Details for MSP Recovery Claims Series LLC v. Amgen, Inc. (S.D. Fla. 2020)
✉ Email this page to a colleague
MSP Recovery Claims Series LLC v. Amgen, Inc. (S.D. Fla. 2020)
Docket | ⤷ Sign Up | Date Filed | 2020-02-06 |
Court | District Court, S.D. Florida | Date Terminated | 2020-02-28 |
Cause | 28:1331 Fed. Question: Anti-trust | Assigned To | Federico A. Moreno |
Jury Demand | Plaintiff | Referred To | |
Patents | 6,001,884; 6,011,068; 6,211,244; 6,313,146; 7,829,595; 9,375,405 | ||
Link to Docket | External link to docket |
Small Molecule Drugs cited in MSP Recovery Claims Series LLC v. Amgen, Inc.
Biologic Drugs cited in MSP Recovery Claims Series LLC v. Amgen, Inc.
Details for MSP Recovery Claims Series LLC v. Amgen, Inc. (S.D. Fla. 2020)
Date Filed | Document No. | Description | Snippet | Link To Document |
---|---|---|---|---|
0000-00-00 | External link to document | |||
2020-02-06 | 1 | covering Sensipar: U.S. Patent Nos. 6,211,244 (expired on October 23, 2015); 6,001,884 (expiry December 14… One of Amgen’s patents for Sensipar, U.S. Patent No. 6,011,068 (the “’068 Patent”), was set to expire…certifications against the patents covering Sensipar. Among these patents was U.S. Patent No. 9,375,405 (the….” Unlike the ’086 patent, the ’405 Patent was a formulation patent, and only covered a new formulation… with the primary substance patent being the ’068 patent. These patents were originally assigned by | External link to document | |
>Date Filed | >Document No. | >Description | >Snippet | >Link To Document |